Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. PTC Therapeutics Inc shares valued at $214,091 were sold by Boulding Mark Elliott on Oct 07 ’25. At $63.43 per share, Boulding Mark Elliott sold 3,375 shares. The insider’s holdings dropped to 103,901 shares worth approximately $7.0 million following the completion of this transaction.
Also, Reeve Emma sold 25,562 shares, netting a total of over 1,686,024 in proceeds. Following the sale of shares at $65.96 each, the insider now holds 10,332 shares.
Before that, Jacobson Allan Steven had sold 12,000 shares from its account. In a trade valued at $780,000, the Director traded PTC Therapeutics Inc shares for $65.00 each. Upon closing the transaction, the insider’s holdings decreased to 12,000 shares, worth approximately $1.18 million.
As published in their initiating research note from Wells Fargo on October 20, 2025, PTC Therapeutics Inc [PTCT] has been an Overweight and the price target has been revised to $73. Analysts at Truist started covering the stock with ‘”a Buy”‘ outlook in a report released in mid June. As of May 09, 2025, BofA Securities has increased its “Neutral” rating to a “Buy” for PTCT. Earlier on May 07, 2025, Citigroup upgraded its rating. Their new recommendation was “a Neutral” for PTCT stock which previously was a “a Sell”.
Analyzing PTCT Stock Performance
On last trading session, PTC Therapeutics Inc [NASDAQ: PTCT] plunged -0.21% to $67.35. The stock’s lowest price that day was $66.438, but it reached a high of $68.14 in the same session. During the last five days, there has been a surge of approximately 1.25%. Over the course of the year, PTC Therapeutics Inc shares have jumped approximately 65.28%. Shares of the company reached a 52-week high of $69.48 on 10/16/25 and a 52-week low of $35.95 on 05/06/25.
Support And Resistance Levels for PTC Therapeutics Inc (PTCT)
According to the 24-hour chart, there is a support level at 66.48, which, if violated, would cause prices to drop to 65.61. In the upper region, resistance lies at 68.18. The next price resistance is at 69.01. RSI (Relative Strength Index) is 61.73 on the 14-day chart, showing neutral technical sentiment.
Is PTC Therapeutics Inc subject to short interest?
Stocks of PTC Therapeutics Inc saw a sharp rise in short interest on 2025-10-15 jumping by 0.52 million shares to 7.82 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 7.29 million shares. A jump of 6.7% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.32 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.32.
Which companies own the most shares of PTC Therapeutics Inc (PTCT)?
In terms of PTC Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 73.5 in the next 12 months, up nearly 8.91% from the previous closing price of $67.49. Analysts anticipate PTC Therapeutics Inc stock to reach 77 by 2025, with the lowest price target being 70. In spite of this, 7 analysts ranked PTC Therapeutics Inc stock as Hold at the end of 2025. On March 11, 2025, BofA Securities assigned a price target of “a Neutral” to the stock and upgraded coverage with a $55.
